Comparative Pharmacology
Head-to-head clinical analysis: MYTREX A versus THIOSULFIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYTREX A versus THIOSULFIL.
MYTREX A vs THIOSULFIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methotrexate inhibits dihydrofolate reductase, leading to depletion of tetrahydrofolate and inhibition of DNA synthesis and cell proliferation. Also has immunomodulatory effects via adenosine release.
Thiosulfil (sulfamethizole) is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folic acid synthesis and thereby nucleic acid production.
Methotrexate (MYTREX A) 7.5-25 mg orally once weekly, or 15-25 mg intramuscularly/subcutaneously once weekly for rheumatoid arthritis; in oncology, dosing varies per protocol.
500 mg orally twice daily for 10-14 days.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours in normal renal function; prolonged to 24-30 hours in moderate to severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 2-4 hours in patients with normal renal function (creatinine clearance >80 mL/min); prolonged to 20-50 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 90% unchanged drug; fecal: <10% via bile; minor hepatic metabolism to inactive metabolites.
Renal: 70-90% as unchanged drug via glomerular filtration and tubular secretion. Biliary/fecal: <5%.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic